ADC地图的三角洲 - 放光特征作为肺癌治疗反应的早期预测指标

调查使用扩散加权MRI衍生的放射素学特征检测早期治疗诱导的肿瘤组织变化的可行性。这项前瞻性观察性研究包括144例接受酪氨酸激酶抑制剂的患者（TKI，n = 64 = 64）或基于Platinum基于Platinum Chemotherapy（Platinum Chemothy），或者是基于Platinum Chemother in = 80）。治疗前一天（基线，所有患者）以及 +1（PBC）或 +7和 +14（TKI）（TKI）几天后，患者接受了扩散加权的MRI。 One hundred ninety-seven radiomics features were extracted from manually delineated tumor volumes.根据CT衍生的RECIST，分析了随时间变化的特征变化与治疗反应（TR）的相关性（TR）和无进展生存期（PFS）。IOUT14个选定的Delta-radiomics特征，6个显示与PFS或TR的显着相关性。 Most significant correlations were found after 14 days.量化ROI异质性的特征，例如短期强调（p = 0.04（pfs）/0.005（tr）），梯度短期强调（p = 0.06（pfs）/0.01（pfs）/0.01（tr））和区域百分比（p = 0.02（pfs）/0.01（pfs）/0.01（tr），较大的特征越来越多。 ROI homogeneity, such as normalized inverse difference (p = 0.01(pfs)/0.04(tr)).这些特征的聚类允许将患者分为较长且较短的生存率组。在治疗开始后数周，肺腺癌的扩散MRI揭示了可量化的组织级别的见解，这些见解与未来治疗（非）反应良好相关。因此，扩散MRI衍生的放射素学显示是预测疗效并可能早期改变治疗过程的早期，无辐射决策支持的希望。delta-telta-放射性质地质地特征特征源自肺腺癌的扩散加权MRI的MRI，作为在恢复治疗后的早期，作为早在reclored and As recomoloty Assist Asist Asist Asist Asist and Trolsistion tremology Asist and Trolsist Asist Asist Asist As Immimist。 imaging takes time to detect TR in lung cancer, diffusion-weighted MRI might identify response earlier. Several radiomics features are significantly correlated with TR and PFS. Radiomics of diffusion-weighted MRI may facilitate patient stratification and management.

Investigate the feasibility of detecting early treatment-induced tumor tissue changes in patients with advanced lung adenocarcinoma using diffusion-weighted MRI-derived radiomics features.This prospective observational study included 144 patients receiving either tyrosine kinase inhibitors (TKI, n = 64) or platinum-based chemotherapy (PBC, n = 80) for the treatment of pulmonary adenocarcinoma. Patients underwent diffusion-weighted MRI the day prior to therapy (baseline, all patients), as well as either + 1 (PBC) or + 7 and + 14 (TKI) days after treatment initiation. One hundred ninety-seven radiomics features were extracted from manually delineated tumor volumes. Feature changes over time were analyzed for correlation with treatment response (TR) according to CT-derived RECIST after 2 months and progression-free survival (PFS).Out of 14 selected delta-radiomics features, 6 showed significant correlations with PFS or TR. Most significant correlations were found after 14 days. Features quantifying ROI heterogeneity, such as short-run emphasis (p = 0.04(pfs)/0.005(tr)), gradient short-run emphasis (p = 0.06(pfs)/0.01(tr)), and zone percentage (p = 0.02(pfs)/0.01(tr)) increased in patients with overall better TR whereas patients with worse overall response showed an increase in features quantifying ROI homogeneity, such as normalized inverse difference (p = 0.01(pfs)/0.04(tr)). Clustering of these features allows stratification of patients into groups of longer and shorter survival.Two weeks after initiation of treatment, diffusion MRI of lung adenocarcinoma reveals quantifiable tissue-level insights that correlate well with future treatment (non-)response. Diffusion MRI-derived radiomics thus shows promise as an early, radiation-free decision-support to predict efficacy and potentially alter the treatment course early.Delta-Radiomics texture features derived from diffusion-weighted MRI of lung adenocarcinoma, acquired as early as 2 weeks after initiation of treatment, are significantly correlated with RECIST TR and PFS as obtained through later morphological imaging.Morphological imaging takes time to detect TR in lung cancer, diffusion-weighted MRI might identify response earlier. Several radiomics features are significantly correlated with TR and PFS. Radiomics of diffusion-weighted MRI may facilitate patient stratification and management.